Actively Recruiting
Optical Genome Mapping in Hematological Malignancies
Led by University Hospital, Brest ยท Updated on 2021-08-17
200
Participants Needed
4
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the potential of optical genome mapping to diagnose patients suspected of having hematologic cancers, including myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (ALL), and other blood-related malignant neoplasms. This observational study aims to assess how this technology can identify chromosomal abnormalities involved in cancer development and progression. Participants provide samples that are analyzed using optical genome mapping to detect new chromosomal anomalies relevant to clinical outcomes and oncogenic pathways. The study tracks these findings from 2021 through 2026 to evaluate the diagnostic value of this method. During the study, patients' samples are collected and examined in a chromosomal genetics laboratory. Researchers review chromosomal data to identify abnormalities linked to hematologic cancers. The study measures the ability of optical genome mapping to improve diagnosis. Participation involves no treatment; instead, it focuses on sample analysis and genetic identification over several years, with a planned end in September 2026.
CONDITIONS
Brief Title
Optical Genome Mapping in Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Minor or adult patients
- Patients with suspected hemopathies submitting a sample for diagnosis or already diagnosed with hemopathy
- No objection to participate or consent given
You will not qualify if you...
- Patients under judicial protection such as guardianship or curatorship
- Refusal to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants provide samples for diagnosis to evaluate chromosomal abnormalities using optical genome mapping.
Visits occur as samples are submitted for diagnosis
Duration - Up to 5 years
Participants are observed over time to identify chromosomal anomalies involved in oncogenic pathways.
Periodic visits depending on clinical needs
Trial Site Locations
Total: 4 locations
1
CHRU de Brest
Brest, France, 29609
Actively Recruiting
2
CH Morlaix, service d'hรฉmato clinique
Morlaix, France
Actively Recruiting
3
CHIC, service d'hรฉmato clinique
Quimper, France
Actively Recruiting
4
CH St Brieuc, service d'hรฉmato clinique
Saint-Brieuc, France
Actively Recruiting
Research Team
M
Marie-Bรฉrengรจre, TROADEC, PhD
N
Nathalie DOUET-GUILBERT, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here